Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study
The Oncologist · 07.09.2023 · 28 (9) · e756-e764
DOI: 10.1093/oncolo/oyad069 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.04.2023. Verfasst von Zola Musimar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Groote Schuur Hospital, University of Cape Town, Cape Town, Western Cape, Republic of South Africa. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma worldwide and particularly in Africa, where the incidence of HIV is the highest in the world. R-CHOP is the standard of care regimen for DLBCL, but access to rituximab is limited in developing countries.
Methods
This is a retrospective cohort study that included all HIV-negative patients with DLBCL who received R-CHOP at a single institution from January 2012 to December 2017. Clinical and demographic data were collected to assess factors that influenced survival.
Results
Seventy-three patients were included. Median age was 55 (17-76), 67.1% of patients were younger than 60 years, and 60.3% were female. Most presented with stages III/IV disease (53.5%) but with good performance status (56.% PS 0 and 1). Progression-free survival at 3 and 5 years was 75% and 69%, and overall survival at 3 and 5 years was 77% and 74%, respectively. Median survival had not been reached with a median follow-up of 3.5 years(0.13-7.9). Overall survival was significantly affected by performance status (P = .04), but not by IPI or age. Survival was significantly associated with response to chemotherapy after 4-5 cycles of R-CHOP (P = 0.005).
Conclusions
Treatment of DLBCL with R-CHOP is feasible and can achieve good outcomes in resource-limited settings with rituximab-based chemotherapy. Poor performance status was the most important adverse prognostic factor in this cohort of HIV-negative patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Oncology Department, Groote Schuur Hospital, University of Cape Town, Cape Town, Western Cape, Republic of South Africa.
- Massachusetts General Hospital Cancer Center and the POETIC Fellowship Exchange Program, Dana Faber, Harvard Cancer Center, Boston, MA, USA.
Zitieren
APA
Musimar, Z., Mpetani, M., Abramson, J. S., Chabner, B. A., & Mohamed, Z. (2023). Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. The Oncologist, 28(9), e756-e764. https://doi.org/10.1093/oncolo/oyad069
Vancouver
Musimar Z, Mpetani M, Abramson JS, Chabner BA, Mohamed Z. Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. The Oncologist. 2023;28(9):e756-e764. doi:10.1093/oncolo/oyad069
BibTeX
@article{Musimar2023,
author = {Musimar, Zola and Mpetani, Mtonga and Abramson, Jeremy S and Chabner, Bruce A and Mohamed, Zainab},
title = {Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {9},
pages = {e756--e764},
doi = {10.1093/oncolo/oyad069}
}
EUVIMED